Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for human biological products, following a submission to the U.S. Patent and Trademark Office (USPTO), Department of Commerce. This determination is published as a required notice.